Blinatumomab Granted Full EU Approval for B-cell Precursor ALL

June 19, 2018 – The European Commission (EC) has granted blinatumomab full marketing authorization for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL), according to Amgen, the developer of the anti-CD19 immunotherapy. The action is based on survival data from the phase III TOWER study, in which the median overall survival (OS) with blinatumomab was 7.7 months versus … (leggi tutto)